Non-Proliferative Diabetic Retinopathy Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Oxurion NV, Ampio Pharmaceuticals, Inc., Glycadia Pharmaceuticals and Ocuphire Pharma

Global Non-Proliferative Diabetic Retinopathy Market reached US$2.68 billion in 2023 and is expected to reach US$4.71 billion by 2031, growing with a CAGR of 7.3% during the forecast period 2024-2031

DataM Intelligence has published a new research report on "Non-Proliferative Diabetic Retinopathy Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/non-proliferative-diabetic-retinopathy-market?sg

USA - Industry Latest News 2025:

✅ 22 May 2025 - FDA approval - Roche: Susvimo (ranibizumab PDS) approved for diabetic retinopathy, making the port-delivery continuous-delivery ranibizumab system available to US retina specialists for DR; positioned as a long-acting delivery option that can reduce injection frequency.

✅ 15 Aug 2025 (reporting) - Ocular Therapeutix: FDA issued a Special Protocol Assessment (SPA) for the registrational trial of AXPAXLI (OTX-TKI) in non-proliferative diabetic retinopathy, giving the company a defined regulatory pathway for a NPDR registrational study.

✅ May 2025 / ARVO 2025 (presentations) - EyePoint / EYP-1901 (PAVIA trial) - 12-month PAVIA data for EYP-1901 (an investigational sustained-delivery anti-VEGF) in NPDR were presented at ARVO 2025 (positive 12-month PAVIA results discussed).

✅ (context / prior 2024-25) - Clinical setbacks noted: earlier-phase setbacks (e.g., Duravyu Phase 2 readouts previously reported) remain part of the landscape and inform ongoing development strategy in 2025.

Japan - Industry Latest News 2025:

✅ June 2025 (June 2 / June 5, 2025 activity reported) - Santen: continued retina pipeline activity and EU approvals for other ophthalmic products (Santen remains active in retinal drug development and regulatory filings in 2025; company highlights include regulatory / market activity for retinal candidates).

✅ 2025 PMDA / regulatory environment updates (May-July 2025) - Japan's regulatory agencies (PMDA, MHLW) continued to update reimbursement and review pathways in 2025 that affect ophthalmology product launches and clinical development timelines.

South Korea - Industry Latest News 2025:

✅ 2025 - Clinical / guideline activity - Korean Diabetes Association 2025 Clinical Practice Guidelines (released 2025) and local clinical activity continued to emphasize screening and early management of diabetic eye disease.

Europe - Industry Latest News 2025:

✅ May 2025 (May 2, 2025) - Topcon Healthcare acquired RetInSight GmbH (retinal AI imaging) - acquisition aimed at accelerating AI-powered retinal imaging and screening workflows (helps earlier detection/referral for diabetic retinopathy including NPDR).

✅ June 10, 2025 / 5 June 2025 - Santen: European Commission / CHMP positive opinion and EC approval activity (example: Ryjunea paediatric myopia approval in Europe announced in June 2025); Santen also reported ongoing retinal development programs in Europe in 2025.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/non-proliferative-diabetic-retinopathy-market?sg

Major Key Players: Bayer AG, Regeneron Pharmaceuticals Inc., Biocon, F. Hoffmann-La Roche, AbbVie Inc., Novartis AG, Oxurion NV, Ampio Pharmaceuticals, Inc., Glycadia Pharmaceuticals and Ocuphire Pharma, Inc.

Market Growth Drivers:

✅ Rising Global Diabetes Prevalence:
The surging number of diabetic patients globally is the primary factor driving NPDR market expansion. As diabetes is the leading cause of vision impairment, early detection and management of NPDR are becoming essential.

✅ Advancements in Retinal Imaging Technologies:
Innovations such as Optical Coherence Tomography (OCT), fundus photography, and AI-powered retinal analysis tools are enhancing the accuracy of NPDR diagnosis, encouraging early treatment adoption.

✅ Government and Nonprofit Initiatives:
Public health programs focusing on diabetes management and vision screening are promoting awareness and routine eye examinations, particularly in developing economies.

✅ Growing Geriatric Population:
The aging demographic, particularly in developed nations, is at higher risk of diabetic complications, contributing to increased screening and treatment rates.

✅ Shift Toward Preventive Eye Care:
Healthcare systems are emphasizing prevention over treatment, with rising investment in early-stage diabetic retinopathy monitoring and digital health solutions for remote retinal assessment.

Segments Covered in the Non-Proliferative Diabetic Retinopathy Market:

By Type (Mild NPDR, Moderate NPDR, Severe NPDR)

By Treatment (Anti-Vascular Endothelial Growth Factor (VFGF) Medication, Intraocular Steroid Injection (Triamcinolone Acetonide (TA)), Steroid Implants, Vitrectomy)

By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Non-Proliferative Diabetic Retinopathy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=non-proliferative-diabetic-retinopathy-market?sg

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Non-Proliferative Diabetic Retinopathy Market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Non-Proliferative Diabetic Retinopathy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Non-Proliferative Diabetic Retinopathy Market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Non-Proliferative Diabetic Retinopathy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Non-Proliferative Diabetic Retinopathy Market?

➠ Who are the global key manufacturers of the Non-Proliferative Diabetic Retinopathy Market Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Non-Proliferative Diabetic Retinopathy Market opportunities and threats faced by the vendors in the global Non-Proliferative Diabetic Retinopathy Market Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Non-Proliferative Diabetic Retinopathy Market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.